ROKIT Healthcare Inc.
Financials
Valuation Metrics
ROKIT Healthcare Inc.'s Market Cap is ₩4928B. At end of 2025 it was ₩1.1T. Ranked #473 of 2,421 in KR market (top 20%), #172 of 1,640 on KOSDAQ (top 10%), #51 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 492.83B KRW | KR#473/2,421 Sec#51/231 |
| Revenue | 32.81B KRW | KR#1,999/2,421 Sec#138/231 |
| Net Income | -12.69B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 108.22B KRW | KR#1,714/2,421 Sec#134/231 |
| Net Assets | 6.72B KRW | KR#2,388/2,421 Sec#227/231 |
| Employees | 86 | KR#1,757/2,421 Sec#140/231 |
| Value | ||
| P/B | 73.32x | KR#2,416/2,421 Sec#231/231 |
| P/S | 15.02x | KR#2,316/2,421 Sec#175/231 |
| FCF Yield | -3.53% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -188.81% | KR#2,377/2,421 Sec#224/231 |
| ROA | -11.73% | KR#2,139/2,421 Sec#163/231 |
| Op. Margin | -46.10% | KR#2,227/2,421 Sec#160/231 |
| Revenue Growth | 106.19% | KR#79/2,421 Sec#15/231 |
| Financial Health | ||
| Debt Ratio | 1509.90% | KR#2,390/2,421 Sec#228/231 |
| Total Debt | 25.05B KRW | KR#1,303/2,421 Sec#102/231 |
| FCF | -17.39B KRW | KR#1,857/2,421 Sec#175/231 |
| Cash | 20.18B KRW | KR#1,249/2,421 Sec#91/231 |
| Current Ratio | 0.89x | KR#1,848/2,421 Sec#178/231 |
| Performance | ||
| 1Y Return | 63.77% | KR#213/2,421 Sec#7/231 |
| 1M Return | -1.05% | KR#1,356/2,421 Sec#101/231 |
| From 52W High | -81.63% | KR#2,357/2,421 Sec#222/231 |
| 1Y MDD | -83.37% | KR#2,343/2,421 Sec#222/231 |
| Trading | ||
| Volume | 81,887 shares | KR#882/2,421 Sec#88/231 |
| Trading Value | 2.31B KRW | KR#523/2,421 Sec#47/231 |
| Foreign Own. | 5.72% | KR#763/2,421 Sec#70/231 |
| Per Share | ||
| EPS | -728 KRW | KR—/2,421 Sec—/231 |
| BPS | 385 KRW | KR#2,400/2,421 Sec#227/231 |
Company Info
Rokit Healthcare, established in 2012, leads the innovative regenerative medicine market. The company has commercialized AI ultra-precision patient-specific organ and skin regeneration platforms, built upon four core technologies including AI for medical lesion modeling and disposable regeneration kits. It provides an economical treatment method for chronic diseases, achieving 90% regeneration with a single procedure, and is expanding its application to cartilage and kidney regeneration platforms. Rokit Healthcare is headquartered in Geumcheon-gu, Seoul Metropolitan City.